The SGLT2i empagliflozin and DPP4i sitagliptin restore insulin sensitivity in HFD/STZ mice by decreasing IRS1 phosphorylation at Tyr632, associated with insulin resistance, and boosting AKT phosphorylation [208]. This evidence concerns the gene AKT1 and Insulin resistance.